Concert Pharmaceuticals Raises Gross Proceeds of $66.4 Million Through Public Offering and Exercise of Warrants
06 Junho 2022 - 05:01PM
Business Wire
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the
closing of its previously announced underwritten public offering of
10,000,000 shares of its common stock to the public at $4.75 per
share. The aggregate gross proceeds to Concert from this offering
were $47.5 million, before deducting underwriting discounts and
commissions and other offering expenses payable by Concert. Concert
also announced the receipt of $18.9 million upon the exercise of
tranche 1 warrants to purchase 3,981 shares of Series X1 Preferred
Stock issued to BVF Partners L.P. and RA Capital Management in
November 2021. Through the public offering and warrant exercise,
Concert raised aggregate gross proceeds of $66.4 million.
Jefferies and Truist Securities acted as joint book-running
managers for the offering. JMP Securities, A Citizens Company, and
Mizuho Securities acted as lead managers, and H.C. Wainwright &
Co. acted as co-manager for the offering.
The offering was made only by means of a written prospectus
supplement and prospectus forming part of a shelf registration
statement previously filed with the Securities and Exchange
Commission (SEC) and declared effective on November 16, 2020. The
final prospectus supplement and accompanying prospectus relating to
the offering was filed with the SEC and is available on the SEC’s
website at www.sec.gov. Copies of the final prospectus supplement
and accompanying prospectus may also be obtained by contacting
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, New York, NY 10022, by telephone at (877)
821-7388, or by email at prospectus_department@jefferies.com or
Truist Securities, Inc., Attention: Prospectus Department, 3333
Peachtree Road NE, 9th floor, Atlanta, Georgia 30326, by telephone
at (800) 685-4786, email:
TruistSecurities.prospectus@Truist.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or other jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
other jurisdiction.
About Concert
Concert Pharmaceuticals is a clinical stage biopharmaceutical
company that is developing small molecule drugs that it discovered
through the application of its DCE Platform® (deuterated chemical
entity platform). Selective incorporation of deuterium into known
molecules has the potential, on a case-by-case basis, to provide
better pharmacokinetic or metabolic properties, thereby enhancing
their clinical safety, tolerability or efficacy. Concert’s lead
product candidate is in late-stage development for the treatment of
alopecia areata, a serious autoimmune dermatological condition.
Concert is also assessing a number of earlier-stage pipeline
candidates.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220606005933/en/
Justine E. Koenigsberg (Investors) Concert Pharmaceuticals, Inc.
(781) 674-5284 ir@concertpharma.com
Kathryn Morris (media) The Yates Network (914) 204-6412
kathryn@theyatesnetwork.com
Concert Pharmaceuticals (NASDAQ:CNCE)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Concert Pharmaceuticals (NASDAQ:CNCE)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024